What Is Retatrutide?
Retatrutide (LY3437943) is a synthetic peptide developed by Eli Lilly with agonist activity at GIP, GLP-1 and glucagon receptors. The 2023 phase 2 study in the New England Journal of Medicine reported mean body-weight reductions of 17.5% at 24 weeks and 24.2% at 48 weeks in the highest dose group. These are trial findings, not outcomes established for catalogue products.
For mechanism of action and clinical-trial context, see our Retatrutide Research Overview. Published clinical research does not establish equivalence of a commercial research sample to the trial material.
For supplier evaluation and interpreting batch documentation, read our Retatrutide research supplier guide.
This page focuses on procurement. The research overview covers the science. For research use only.
Retatrutide Products
Two concentrations available, supplied in boxes of 10 research-grade vials.
Why Researchers Choose Eternal Peptides Wholesale
Published Batch Reports
Kovera Labs reports for the listed Retatrutide batches (EP-260514-RE10 for 10mg and EP-260514-RE20 for 20mg) record purity and identity by HPLC, plus endotoxin, heavy metals and sterility results. Each report lists its batch number and report ID.
Australian-Owned
Not an overseas supplier behind an Australian domain. Eternal Peptides Wholesale is an Australian business. Contact us about supplier and invoicing documentation before ordering.
COAs Available Before Purchase
Use the verification link attached to each Kovera Labs certificate. Compare its report identifier, batch, test scope and results with the laboratory record before relying on the document.
Wholesale Box Pricing
Products are supplied in box quantities (10 vials per box). No per-vial markups. Pricing structure designed for research procurement budgets, not single-use retail.
About Kovera Labs Testing
EPW publishes the supplied Kovera Labs certificates so researchers can inspect their sample identifiers, methods, results and limitations. The certificates are analytical records for submitted samples; their publication is not a claim of laboratory accreditation or clinical approval.
Use the “Verify on Kovera Labs” link for the individual certificate, then compare the laboratory record with the displayed report: sample or report identifier, product, strength, batch, dates, tests and results. The certificate and its Kovera Labs verification record carry the same report ID, so the two can be checked side by side.
Kovera Labs reports for the listed Retatrutide batches (EP-260514-RE10 for 10mg and EP-260514-RE20 for 20mg) record purity and identity by HPLC, plus endotoxin, heavy metals and sterility results. Each report lists its batch number and report ID.
Third-Party Lab Reports
Published Kovera Labs reports for the listed Retatrutide samples. Each certificate shows its batch number and links to its Kovera Labs verification record.
RT10 (10mg)
View the current Kovera Labs reports and laboratory verification links
RT20 (20mg)
Regulatory Context for GLP-1 Class Compounds in Australia
Eternal Peptides Wholesale supplies catalogue products for qualified laboratory research only. Research-use wording does not remove applicable Australian legal requirements. Products are not supplied for human therapeutic use or compounding for human administration. Customers should check the current requirements for their specific research context.
Frequently Asked Questions
Where can I buy Retatrutide in Australia? +
Eternal Peptides Wholesale is an Australian-owned online supplier supplying Retatrutide for research purposes. RT10 (10mg, box of 10) is $544.50 and RT20 (20mg, box of 10) is $891.00. Check the product page for available batch reports. Free shipping. For research use only.
What is the difference between RT10 and RT20? +
RT10 contains 10mg of Retatrutide per vial (box of 10 vials, $544.50). RT20 contains 20mg of Retatrutide per vial (box of 10 vials, $891.00). Both are supplied as boxes of 10 vials. Concentration selection depends on your research protocol. Batch-specific Kovera Labs COAs are on each product page. For research use only.
How is the quality of Retatrutide verified? +
Kovera Labs reports for the listed Retatrutide batches (EP-260514-RE10 for 10mg and EP-260514-RE20 for 20mg) record purity and identity by HPLC, plus endotoxin, heavy metals and sterility results. Each report lists its batch number and report ID.
What is Retatrutide's mechanism of action? +
Retatrutide has agonist activity at GIP, GLP-1 and glucagon receptors. See the Retatrutide Research Overview for receptor mechanisms and cited clinical-trial findings. For research use only.
Is Retatrutide approved for human use in Australia? +
No. Retatrutide is currently in Phase 3 clinical development and is not approved by the TGA for therapeutic use in Australia. Eternal Peptides Wholesale supplies Retatrutide for qualified laboratory research use only. It is not for human therapeutic use or consumption. GLP-1 class compounds have been subject to increased TGA regulatory attention since October 2024. Customers should seek independent legal and compliance advice regarding their specific research context.
How long does shipping take? +
Orders are typically processed within 1–5 business days. Estimated delivery is 5–7 business days after dispatch, depending on destination and customs clearance. Dispatch origin can vary, including offshore fulfilment; Australian business ownership does not guarantee domestic stock or customs-free delivery. Consult our Shipping Policy for current processing and delivery estimates. Certificates of Analysis are included with every order. Contact us before ordering if your protocol has specific temperature or logistics requirements.
Related Research Resources
Related research articles
- MOTS-c: why an exercise study is not a trial of a peptide injection
- Peptides in Australia: what to check before trusting a buying claim
- Avoiding Counterfeit Peptides: Verify COAs and Peptide Content
- In Vitro Studies Using Retatrutide: A Researcher’s Guide
- Retatrutide Mechanism of Action: What Studies Show
Testing references updated 1 November 2026 for the published Kovera Labs report set. Original research and catalogue snapshot dates remain as stated.